Management of dyschromias in ethnic skin

Dermatologic Therapy

Volumn 17, Issue 2, 2004, Pages 151-157

  Halder, Rebat M ^a,b   Richards, Georgianna M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Ethnic skin; Hyperpigmentation; Hypopigmentation; Vitiligo

Indexed keywords

2 HYDROXYACID; 4 S CYSTEAMINYLPHENOL; ARBUTIN; ASCORBIC ACID; AZELAIC ACID; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLYCYRRHIZA EXTRACT; HYDROQUINONE; KOJIC ACID; METHOXSALEN; MONOBENZONE; N ACETYL 4 CYSTEAMINYLPHENOL; RETINOIC ACID; RETINOID; TAR; TOPICAL AGENT; UNCLASSIFIED DRUG;

CHLOASMA; CONTACT DERMATITIS; DEPIGMENTATION; DERMATITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERYTHEMA; ETHNIC GROUP; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IRRITANT DERMATITIS; NAIL COLOR DEFECT; PIGMENT DISORDER; POSTINFLAMMATORY CONTACT DERMATITIS; PUVA; RETINOID HYPERPIGMENTATION; REVIEW; SKIN ALLERGY; SKIN PIGMENTATION; VITILIGO;

ADMINISTRATION, CUTANEOUS; AFRICAN CONTINENTAL ANCESTRY GROUP; ARBUTIN; DICARBOXYLIC ACIDS; HUMANS; HYDROQUINONES; KERATOLYTIC AGENTS; PIGMENTATION DISORDERS; PYRONES; TRETINOIN;

EID: 2442718938     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04015.x     Document Type: Review

References (37)

1. Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol 2003: 48 (Suppl.): S143-S148.
2. Grimes PE, Stockton T. Pigmentary disorders in blacks. Derm Clinics 1988: 6: 271-281.
3. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995: 131: 1453-1457.
4. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001: 2: 213-217.
5. Alena F, Dixon W, Thomas P, Jimbow K. Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-S-cysteaminylphenol in black and yellow hair follicles. J Invest Dermatol 1995: 104: 792-797.
6. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991: 127: 1528-1534.
7. Nguyen QH, Bui TP. Azelaic acid. Pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol 1995: 34: 75-84.
8. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis 1996: 57: 36-45.
9. Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1998: 20: 945-959.
10. Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991: 30: 893-895.
11. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol (Stockh) 1989: 143 (Suppl.): 58-61.
12. Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis 1998: 39: 86-87.
13. Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis 1995: 32: 9-13.
14. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharm Exp Ther 1996: 276: 765-769.
15. Lei TC, Virador VM, Vieira WD, Hearing VJ. A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro. Anal Biochem 2002: 305: 260-268.
16. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The Inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998: 11: 355-361.
17. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Medical 1993: 328: 1438-1443.
18. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 1994: 130: 727-733.
19. Griffiths CE, Finkel LI, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 1993: 129: 415-421.
20. Perez A, Sanchez JL. Treatment of acne vulgaris in skin of color. Cosmetic Derm 2003: 16 (Suppl. 3): 23-28.
21. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002: 29: 539-540.
22. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975: 111: 40-48.
23. Galderma Laboratories. Data on file. Fort Worth, TX: Galderma Laboratories, 2003.
24. Urbanek RW. Tar vitiligo therapy. J Am Acad Dermatol 1983: 8: 755.
25. Leone G, Iacovelli P, Paro Vidolin A, Picardo M. Monochromatic excimer light 308-nm in the treatment of vitiligo: a pilot study. J Euro Acad Dermatol Venereol 2003: 17: 531-537.
26. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser; a pilot study. J Am Acad Dermatol 2002: 46: 727-731.
27. Dierickx CC. IL-37 Lasers in pigmentary disorders. Pigment Cell Res 2003: 16: 590.
28. Kostovick K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003: 11: 163-170.
29. Halder RM. Topical PUVA therapy for vitiligo. Dermatol Nurs 1991: 3: 178-198.
30. Arrunategui A, Arroyo C, Garcia L, et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994: 33: 484-487.
31. Norris DA, Horikawa T, Morelli JG. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994: 7: 193-203.
32. Scherschun L, Kim JJ, Lim H. Narrow-band UVB is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001: 44: 999-1003.
33. Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol Clinics 2000: 18: 79-89.
34. Falabella R, Barona MI, Escobar C, et al. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg 1995: 21: 853-857.
35. Bose S. Modified Thiersch grafting in stable vitiligo. J Dermatol 1996: 23: 362-364.
36. Falabella R. Surgical therapies for vitiligo. Clinics Dermatol 1997: 15: 927-247.
37. Halder RM, Brooks HL. Medical therapies for vitiligo. Dermatologic Ther 2001: 14: 1-6.